Acadia Pharma (ACAD) Misses Q1 EPS by 3c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $22.09 --0%
Revenue Growth %: +12.1%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +12.1%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of $0.02, $0.03 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $268.06 million versus the consensus estimate of $280.92 million.
GUIDANCE:
Acadia Pharma sees FY2026 revenue of $1.22-1.28 billion, versus the consensus of $1.23 billion.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
- Goldman sees inflation cooling by 2027 as AI and energy effects fade
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
